Full video transcriptClick to expand
Auto-generated transcript of @aubergine_avenger's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00These fantastic four together utilize on a fat loss phase.
- 0:05Oh, mama's seat.
- 0:08You are going to have a sizzling shape with a glutes and legs are much fuller.
- 0:12The waist is tighter without having to turn to anabolic steroids.
- 0:16First of all, retro true tide is going to counsel our food noise,
- 0:20increase your fat loss ability and increase your insulin sensitivity.
- 0:24MoSi is going to supercharge your mitochondria,
- 0:27allow you to be able to train harder, perform a better in the gym,
- 0:31recover better from the gym,
- 0:32also increase insulin sensitivity and burn more body fat from the fat.
- 0:38That fucking retro true tide is releasing.
- 0:40CJC and IP Morlin will drive up your own natural production of growth on an IGF-1,
- 0:48allowing you to have a fuller look, better fat loss, better skin quality, better recovery.
- 0:53These four together, you enhance the results of the work that you're putting in
- 1:00without having to jeopardize your hormone system and without fucking up your body.
Peptide stacks for women in fat loss: what the science says
Quick answer
The creator promotes a four-compound stack, retatrutide, MOTS-c, CJC-1295, and ipamorelin, as a fat loss and body composition tool for women that avoids hormonal disruption. Retatrutide remains in Phase 2 clinical trials with no FDA approval for general use, and CJC-1295 plus ipamorelin are known to elevate GH and IGF-1 through endocrine mechanisms, directly contradicting the claim that this stack leaves the hormone system unaffected. MOTS-c has no established human safety profile or approved clinical indication, making stack-level safety claims for this combination premature and unsupported.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Peptide stacks for women in fat loss: what the science says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial
Primary human trial source for retatrutide obesity efficacy and safety discussions.
PubMed
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease
Used when retatrutide pages touch liver-fat, MASLD, and metabolic outcomes.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Peptide stacks for women in fat loss: what the science says is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Peptide stacks for women in fat loss: what the science says" from Afser Choudry. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator promotes a four-compound stack, retatrutide, MOTS-c, CJC-1295, and ipamorelin, as a fat loss and body composition tool for women that avoids hormonal disruption.
The reason this review is not generic is the source wording and the canonical claim label "peptides a fantastic stack for women to use in a fat loss phase to ke." In this clip, the useful excerpt is: "These fantastic four together utilize on a fat loss phase." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), Discontinuing glucagon-like peptide-1 receptor agonists and body habitus (2025), and Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition (2025), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator promotes a four-compound stack, retatrutide, MOTS-c, CJC-1295, and ipamorelin, as a fat loss and body composition tool for women that avoids hormonal disruption.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator promotes a four-compound stack, retatrutide, MOTS-c, CJC-1295, and ipamorelin, as a fat loss and body composition tool for women that avoids hormonal disruption. Retatrutide remains in Phase 2 clinical trials with no FDA approval for general use, and CJC-1295 plus ipamorelin are known to elevate GH and IGF-1 through endocrine mechanisms, directly contradicting the claim that this stack leaves the hormone system unaffected. MOTS-c has no established human safety profile or approved clinical indication, making stack-level safety claims for this combination premature and unsupported.
- Retatrutide is in Phase 2 trials only (Jastreboff et al., 2023, NEJM); any version currently circulating outside trials is compounded or gray-market with unverified purity.
- CJC-1295 does raise GH and IGF-1 in humans per Teichman et al. (2006), but body composition benefits in non-deficient healthy women have not been established in peer-reviewed trials.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Retatrutide is in Phase 2 trials only (Jastreboff et al., 2023, NEJM); any version currently circulating outside trials is compounded or gray-market with unverified purity.
- CJC-1295 does raise GH and IGF-1 in humans per Teichman et al. (2006), but body composition benefits in non-deficient healthy women have not been established in peer-reviewed trials.
- MOTS-c has no FDA approval, no established human dosing protocol, and no published long-term safety data in humans.
- Calling this stack 'non-hormonal' is factually wrong: GH secretagogues work by altering pituitary hormone release, which is a direct endocrine intervention by definition.
- GLP-1 receptor agonists are associated with lean mass loss alongside fat loss during caloric restriction, a tradeoff the creator does not mention.
- No published study has examined the safety or efficacy of combining these four specific compounds in humans, making stack-level outcome claims speculative.
- The disclaimer about consulting a medical professional does not offset specific efficacy claims that exceed what the current evidence supports.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @aubergine_avenger actually say?
The creator stacked four compounds: retatrutide (called "retro true tide"), MOTS-c, CJC-1295, and ipamorelin. The pitch is that these four together can give women "a fuller look" in the glutes and legs, a "tighter waist," better fat loss, and improved recovery, all without touching anabolic steroids or "fucking up your body." That last claim is doing a lot of heavy lifting, and it deserves serious scrutiny.
To be fair, the creator does note a disclaimer about consulting a medical professional. But disclaimers don't neutralize claims. Saying retatrutide will "counsel our food noise" and MOTS-c will "supercharge your mitochondria" are specific, consequential assertions that need evidence behind them, not just a verbal shrug at the end.
Does the science back this up?
Partially, and unevenly across the four compounds. Retatrutide has the strongest data, but it comes from early-phase trials in controlled settings. The rest of this stack is built on animal studies and thin human evidence.
Retatrutide is a triple agonist (GIP, GLP-1, glucagon receptors) currently in Phase 2 trials. Jastreboff et al. (2023, NEJM) showed meaningful weight loss in adults with obesity, and appetite suppression is a legitimate mechanism. But "food noise" reduction, while a real patient-reported phenomenon with GLP-1 agonists, is not a standardized clinical outcome. MOTS-c is a mitochondrial-derived peptide. Kim et al. (2021, Nature Communications) showed metabolic effects in mice and some human data around exercise performance, but "supercharge your mitochondria" is not how any published researcher has described the effect size. CJC-1295 and ipamorelin do stimulate growth hormone release. Teichman et al. (2006, Journal of Clinical Endocrinology and Metabolism) confirmed sustained GH elevation with CJC-1295, but translating that into "fuller glutes" requires a chain of assumptions the data does not support.
What did they get wrong (or right)?
Right: The general mechanism claims for retatrutide and the GHRH/GHRP combination are not fabricated. GLP-1 class drugs do reduce appetite. GH secretagogues do raise IGF-1. Giving credit where it is due matters.
Wrong, and meaningfully so: The framing that this stack will not "jeopardize your hormone system" is not supported. Exogenous modulation of growth hormone pulsatility via CJC-1295 and ipamorelin absolutely affects the endocrine axis. Continuous GH stimulation can suppress natural GHRH signaling over time. That is, by definition, a hormonal intervention. The creator is drawing a semantic line between "peptides" and "steroids" as if peptides carry no physiological risk. That line does not exist in endocrinology. Additionally, retatrutide is not approved by the FDA for human use outside of clinical trials. Calling it a "fantastic" fat loss tool without that context is a significant omission.
The safety gap
MOTS-c has no established human dosing protocol, no long-term safety data in humans, and no FDA approval. Stacking it with a GLP-1 agonist and two GH secretagogues creates a compound interaction profile that has not been studied. Saying this does not "fuck up your body" is speculation, not evidence.
What should you actually know?
If you are a woman considering any of these compounds for fat loss, here is what the evidence actually supports and what it does not.
- Retatrutide is in clinical trials, not on the market. Any version you access now is compounded or gray-market, with no guaranteed purity or dosing accuracy.
- GLP-1 class peptides have real side effects including nausea, muscle mass loss during caloric restriction, and gastrointestinal distress. These are not minor.
- CJC-1295 and ipamorelin do raise GH and IGF-1, but the body composition benefit in healthy, non-deficient women is not well-established in peer-reviewed human trials.
- MOTS-c research is genuinely interesting, but interesting is not the same as proven safe or effective for the use case being described here.
- The "no hormonal impact" claim is false by definition. Growth hormone secretagogues are hormonal interventions. Anyone telling you otherwise is either uninformed or hoping you are.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Afser Choudry · TikTok creator
15.5K views on this video
A FANTASTIC stack for women to use in a fat loss phase.. to keep and even build their shape while dropping body fat. Disclaimer: I do NOT encourage the use of steroids, research compounds or substances not approved for human use. Always consult a medical professional before considering any enhancement protocol.
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about retatrutide?
Retatrutide is in Phase 2 trials only (Jastreboff et al., 2023, NEJM); any version currently circulating outside trials is compounded or gray-market with unverified purity.
What does the video say about cjc-1295 does raise gh?
CJC-1295 does raise GH and IGF-1 in humans per Teichman et al. (2006), but body composition benefits in non-deficient healthy women have not been established in peer-reviewed trials.
What does the video say about mots-c has no fda approval, no established human dosing protocol,?
MOTS-c has no FDA approval, no established human dosing protocol, and no published long-term safety data in humans.
What does the video say about calling this stack 'non-hormonal'?
Calling this stack 'non-hormonal' is factually wrong: GH secretagogues work by altering pituitary hormone release, which is a direct endocrine intervention by definition.
What does the video say about glp-1 receptor agonists?
GLP-1 receptor agonists are associated with lean mass loss alongside fat loss during caloric restriction, a tradeoff the creator does not mention.
What does the video say about no published study has examined the safety?
No published study has examined the safety or efficacy of combining these four specific compounds in humans, making stack-level outcome claims speculative.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Afser Choudry, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.